Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 6/20 | 0.50 |
| ▸ | MMP3 | P08254 | 10/20 | 0.46 |
| ▸ | MMP9 | P14780 | 7/20 | 0.46 |
| ▸ | BIRC2 | Q13490 | 2/20 | 0.42 |
| ▸ | MMP1 | P03956 | 2/20 | 0.42 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.37 |
| ▸ | PLA2G5 | P39877 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23613615 | 0.88 | CTSK (0.51) | CTSKMMP3MMP9BIRC2MMP1 | |
| SCHEMBL23394724 | 0.84 | CAPN1 (0.42) | CTSKMMP3MMP9BIRC2 | |
| SCHEMBL14876797 | 0.84 | CTSK (0.56) | CTSKPLA2G2APLA2G5 | |
| SCHEMBL258985 | 0.84 | CTSK (0.56) | CTSKMMP3MMP9BIRC2 | |
| SCHEMBL18328801 | 0.84 | CTSK (0.56) | CTSKMMP3MMP9BIRC2 | |
| SCHEMBL1783728 | 0.84 | CTSK (0.56) | CTSKMMP3MMP9BIRC2 | |
| SCHEMBL231491 | 0.84 | CTSK (0.56) | CTSKMMP3MMP9BIRC2 | |
| SCHEMBL4292353 | 0.84 | CTSK (0.56) | CTSKMMP3MMP9BIRC2 | |
| SCHEMBL20756961 | 0.84 | CTSK (0.56) | CTSKMMP3MMP9BIRC2 | |
| SCHEMBL1783726 | 0.84 | CTSK (0.56) | CTSKMMP3MMP9BIRC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11014953-B2 | Trigger-activatable metabolic sugar precursors for cancer-selective labeling and targeting | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2021-05-25 | — | — | US | disclosed |
| US-9956297-B2 | FAP-activated proteasome inhibitors for treating solid tumors | TRUSTEES OF TUFTS COLLEGE (US) | 2018-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11014953-B2 | Trigger-activatable metabolic sugar precursors for cancer-selective labeling and targeting | GPI, SLC2A1, SLC2A4 | CTSK 667/4885MMP3 2464/4885MMP9 2906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.